专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08658602B2 Multimeric constructs 有权
标题翻译：多聚体构建体
公开(公告)号：US08658602B2
公开(公告)日：2014-02-25
申请号：US13019432
申请日：2011-02-02
申请人： Abraham Scaria , Peter Pechan , Samuel Wadsworth
发明人： Abraham Scaria , Peter Pechan , Samuel Wadsworth
IPC分类号： C12P21/04 , C12N15/00 , C12N9/48 , A61K38/17 , C07K14/705 , C07K14/71 , C07H21/04
CPC分类号： C07K16/22 , A61K38/00 , C07K14/475 , C07K14/52 , C07K14/705 , C07K2319/30 , C07K2319/32 , C07K2319/735 , C12P21/00
摘要： Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular degeneration, cancer, psoriasis, proliferative diabetic retinopathy, asthma, uveitis, osteoarthritis, and rheumatoid arthritis. The same means of multimerization used for an Iglike domain of Flt-1, i.e., a linker and a multimerization domain, can be used for other polypeptides, including extracellular receptors, antibody variable regions, cytokines, chemokines, and growth factors.
摘要翻译： Flt-1的Ig样结构域的多聚体融合蛋白通过包含连接体部分而被赋予功能。编码融合蛋白和表达融合蛋白的宿主细胞的载体可用于治疗性地阻断具有与新血管形成相关的病理状况的个体的新生血管形成。这些病症包括年龄相关性黄斑变性，癌症，牛皮癣，增殖性糖尿病性视网膜病变，哮喘，葡萄膜炎，骨关节炎和类风湿性关节炎。用于Flt-1的Ig型结构域，即接头和多聚化结构域的相同的多聚化方法可用于其它多肽，包括细胞外受体，抗体可变区，细胞因子，趋化因子和生长因子。

2. 发明申请

US20110034539A1 METHODS FOR TREATING BLOOD COAGULATION DISORDERS 审中-公开
标题翻译：治疗血液凝血障碍的方法
公开(公告)号：US20110034539A1
公开(公告)日：2011-02-10
申请号：US12566831
申请日：2009-09-25
申请人： Samuel WADSWORTH , Abraham SCARIA
发明人： Samuel WADSWORTH , Abraham SCARIA
IPC分类号： A61K31/713 , A61P7/02
CPC分类号： C12N9/6437 , A61K48/00 , C07K2319/02 , C12N2799/021 , C12Y304/21021
摘要： The present invention relates to a method of treating an individual having a blood coagulation defect (e.g., hemophilia A, hemophilia B), comprising administering to the individual an effective amount of a DNA vector encoding modified Factor VII (FVII), wherein the modified Factor VII leads to generation of Factor VIIa in vivo. In a particular embodiment, the invention pertains to a method of treating an individual having a blood coagulation defect comprising administering to the individual an effective amount of a nucleic acid encoding a modified FVII wherein the modified FVII comprises a signal which codes for precursor cleavage by furin at the activation cleavage site of the modified FVII. The invention also relates to a method of treating an individual having a blood coagulation disorder comprising administering to the individual an effective amount of a nucleic acid encoding the light chain of human FVII and a nucleic acid encoding the heavy chain of human FVII operably linked to a leader sequence. Compositions, expression vectors and host cells comprising nucleic acid which encodes a modified Factor VII, wherein the modified Factor VII leads to generation of Factor VIIa in vivo is also encompassed by the present invention.
摘要翻译：本发明涉及一种治疗患有血液凝固缺陷的个体（例如，血友病A，血友病B）的方法，包括向个体施用有效量的编码修饰因子VII（FVII）的DNA载体，其中修饰因子 VII导致体内因子VIIa的产生。在一个具体实施方案中，本发明涉及治疗具有凝血缺陷的个体的方法，其包括向个体施用有效量的编码修饰的FVII的核酸，其中修饰的FVII包含编码弗林蛋白酶前体切割的信号在修饰的FVII的激活切割位点。本发明还涉及一种治疗患有血液凝固病症的个体的方法，包括向个体施用有效量的编码人FVII轻链的核酸和编码人FVII重链的核酸，其可操作地连接到领导序列。包含编码修饰因子VII的核酸的组合物，表达载体和宿主细胞，其中修饰的因子VII导致体内产生因子VIIa也包括在本发明中。

3. 发明申请

US20100322894A1 Combination Therapies for Treating Type 1 Diabetes 有权
标题翻译：治疗1型糖尿病的联合疗法
公开(公告)号：US20100322894A1
公开(公告)日：2010-12-23
申请号：US12680614
申请日：2008-09-30
申请人： Mark A Atkinson , Scott Eisenbeis , Donna Armentano , Abraham Scaria , Tracey Lodie
发明人： Mark A Atkinson , Scott Eisenbeis , Donna Armentano , Abraham Scaria , Tracey Lodie
IPC分类号： A61K38/19 , A61K39/395 , A61K35/12 , A61K38/26 , A61K38/18 , A61K31/436 , A61P37/06 , A61P29/00 , A61P3/10 , A61P19/02
CPC分类号： A61K39/39541 , A61K31/436 , A61K35/28 , A61K38/193 , A61K38/26 , A61K45/06 , A61K2300/00
摘要： In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes.
摘要翻译：根据本发明，组合疗法可用于调节患者的免疫应答，以防止，延迟和/或逆转1型糖尿病。

4. 发明授权

US10822391B2 Fusion proteins and methods for inhibiting IL-17 pathways 有权
公开(公告)号：US10822391B2
公开(公告)日：2020-11-03
申请号：US12731772
申请日：2010-03-25
申请人： Abraham Scaria , Gary White
发明人： Abraham Scaria , Gary White
IPC分类号： C07K19/00 , C07K14/715 , A61K38/00
摘要： Fusion proteins including an IL-17 receptor with a multimerization domain, or an IL-23 receptor and a multimerization domain, and recombinant viral vectors encoding such fusions, are described. The fusion proteins and vectors encoding such fusions, alone or in combination, can be used in methods for modulating the IL-17 and IL-23 signaling pathways and for treating or preventing diseases mediated by interleukin-17 and interleukin-23, such as immune-related and inflammatory diseases.

5. 发明授权

US08758761B2 Combination therapies for treating type 1 diabetes 有权
标题翻译：用于治疗1型糖尿病的联合疗法
公开(公告)号：US08758761B2
公开(公告)日：2014-06-24
申请号：US12680614
申请日：2008-09-30
申请人： Mark A. Atkinson , Scott Eisenbeis , Donna Armentano , Abraham Scaria , Tracey Lodie
发明人： Mark A. Atkinson , Scott Eisenbeis , Donna Armentano , Abraham Scaria , Tracey Lodie
IPC分类号： A61K39/00 , A61K39/38
CPC分类号： A61K39/39541 , A61K31/436 , A61K35/28 , A61K38/193 , A61K38/26 , A61K45/06 , A61K2300/00
摘要： In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes.
摘要翻译：根据本发明，组合疗法可用于调节患者的免疫应答，以防止，延迟和/或逆转1型糖尿病。

6. 发明申请

US20110268735A1 MULTIMERIC CONSTRUCTS 有权
标题翻译：多媒体构造
公开(公告)号：US20110268735A1
公开(公告)日：2011-11-03
申请号：US13019432
申请日：2011-02-02
申请人： Abraham Scaria , Peter Pechan , Samuel Wadsworth
发明人： Abraham Scaria , Peter Pechan , Samuel Wadsworth
IPC分类号： A61K39/395 , C12N5/071 , C12N15/85 , C07K16/22 , A61P11/06 , A61K31/7088 , A61P27/02 , A61P3/10 , A61P19/02 , A61P35/00 , C12P21/00 , C07H21/04
CPC分类号： C07K16/22 , A61K38/00 , C07K14/475 , C07K14/52 , C07K14/705 , C07K2319/30 , C07K2319/32 , C07K2319/735 , C12P21/00
摘要： Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular degeneration, cancer, psoriasis, proliferative diabetic retinopathy, asthma, uveitis, osteoarthritis, and rheumatoid arthritis. The same means of multimerization used for an Iglike domain of Flt-1, i.e., a linker and a multimerization domain, can be used for other polypeptides, including extracellular receptors, antibody variable regions, cytokines, chemokines, and growth factors.
摘要翻译： Flt-1的Ig样结构域的多聚体融合蛋白通过包含连接体部分而被赋予功能。编码融合蛋白和表达融合蛋白的宿主细胞的载体可用于治疗性地阻断具有与新血管形成相关的病理状况的个体的新生血管形成。这些病症包括年龄相关性黄斑变性，癌症，牛皮癣，增殖性糖尿病性视网膜病变，哮喘，葡萄膜炎，骨关节炎和类风湿性关节炎。用于Flt-1的Ig型结构域，即接头和多聚化结构域的相同的多聚化方法可用于其它多肽，包括细胞外受体，抗体可变区，细胞因子，趋化因子和生长因子。

7. 发明申请

US20090162345A1 Materials and Methods for Reversing Type-1 Diabetes 审中-公开
标题翻译： 1型糖尿病逆转材料与方法
公开(公告)号：US20090162345A1
公开(公告)日：2009-06-25
申请号：US12094866
申请日：2006-11-29
申请人： Mark A. Atkinson , Gregory Simon , Clive Henry Wasserfall , Abraham Scaria , Desmond A. Schatz , Donna Armentano , Srinivas Shankara
发明人： Mark A. Atkinson , Gregory Simon , Clive Henry Wasserfall , Abraham Scaria , Desmond A. Schatz , Donna Armentano , Srinivas Shankara
IPC分类号： A61K39/395 , A61P3/10
CPC分类号： C07K16/28 , A61K39/39541 , A61K2039/505 , A61K2300/00
摘要： In accordance with the subject invention, anti-thymocyte globulin (ATG) can be used to modulate a patient's immune response in order to prevent and/or delay the onset or the progression of type 1 diabetes. ATG treatment augments CD4+CD25+ cell frequencies and their functional activities.
摘要翻译：根据本发明，抗胸腺细胞球蛋白（ATG）可用于调节患者的免疫应答，以预防和/或延缓1型糖尿病的发病或进展。 ATG治疗增加CD4 + CD25 +细胞频率及其功能活动。

8. 发明授权

US07928072B2 Multimeric constructs 有权
标题翻译：多聚体构建体
公开(公告)号：US07928072B2
公开(公告)日：2011-04-19
申请号：US11716794
申请日：2007-03-12
申请人： Abraham Scaria , Peter Pechan , Samuel Wadsworth
发明人： Abraham Scaria , Peter Pechan , Samuel Wadsworth
IPC分类号： C12P21/04 , C12N15/00 , C12N9/48 , A61K38/17 , C07K14/705 , C07K14/71 , C07H21/04
CPC分类号： C07K16/22 , A61K38/00 , C07K14/475 , C07K14/52 , C07K14/705 , C07K2319/30 , C07K2319/32 , C07K2319/735 , C12P21/00
摘要： Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular degeneration, cancer, psoriasis, proliferative diabetic retinopathy, asthma, uveitis, osteoarthritis, and rheumatoid arthritis. The same means of multimerization used for an Iglike domain of Flt-1, i.e., a linker and a multimerization domain, can be used for other polypeptides, including extracellular receptors, antibody variable regions, cytokines, chemokines, and growth factors.
摘要翻译： Flt-1的Ig样结构域的多聚体融合蛋白通过包含连接体部分而被赋予功能。编码融合蛋白和表达融合蛋白的宿主细胞的载体可用于治疗性地阻断具有与新血管形成相关的病理状况的个体的新生血管形成。这些病症包括年龄相关性黄斑变性，癌症，牛皮癣，增殖性糖尿病性视网膜病变，哮喘，葡萄膜炎，骨关节炎和类风湿性关节炎。用于Flt-1的Ig型结构域，即接头和多聚化结构域的相同的多聚化方法可用于其它多肽，包括细胞外受体，抗体可变区，细胞因子，趋化因子和生长因子。

9. 发明授权

US07615537B2 Methods for treating blood coagulation disorders 有权
标题翻译：治疗凝血障碍的方法
公开(公告)号：US07615537B2
公开(公告)日：2009-11-10
申请号：US10057620
申请日：2001-10-25
申请人： Abraham Scaria , Samuel C. Wadsworth
发明人： Abraham Scaria , Samuel C. Wadsworth
IPC分类号： A61K48/00 , C12N15/63
CPC分类号： C12N9/6437 , A61K48/00 , C07K2319/02 , C12N2799/021 , C12Y304/21021
摘要： The present invention relates to a method of treating an individual having a blood coagulation defect (e.g., hemophilia A, hemophilia B), comprising administering to the individual an effective amount of a DNA vector encoding modified Factor VII (FVII), wherein the modified Factor VII leads to generation of Factor VIIa in vivo. In a particular embodiment, the invention pertains to a method of treating an individual having a blood coagulation defect comprising administering to the individual an effective amount of a nucleic acid encoding a modified FVII wherein the modified FVII comprises a signal which codes for precursor cleavage by furin at the activation cleavage site of the modified FVII. The invention also relates to a method of treating an individual having a blood coagulation disorder comprising administering to the individual an effective amount of a nucleic acid encoding the light chain of human FVII and a nucleic acid encoding the heavy chain of human FVII operably linked to a leader sequence. Compositions, expression vectors and host cells comprising nucleic acid which encodes a modified Factor VII, wherein the modified Factor VII leads to generation of Factor VIIa in vivo is also encompassed by the present invention.
摘要翻译：本发明涉及一种治疗患有血液凝固缺陷的个体（例如，血友病A，血友病B）的方法，包括向个体施用有效量的编码修饰因子VII（FVII）的DNA载体，其中修饰因子 VII导致体内因子VIIa的产生。在一个具体实施方案中，本发明涉及治疗具有凝血缺陷的个体的方法，其包括向个体施用有效量的编码修饰的FVII的核酸，其中修饰的FVII包含编码弗林蛋白酶前体切割的信号在修饰的FVII的激活切割位点。本发明还涉及一种治疗患有血液凝固病症的个体的方法，包括向个体施用有效量的编码人FVII轻链的核酸和编码人FVII重链的核酸，其可操作地连接到领导序列。包含编码修饰因子VII的核酸的组合物，表达载体和宿主细胞，其中修饰的因子VII导致体内产生因子VIIa也包括在本发明中。

10. 发明申请

US20080096808A1 USE OF RAPAMYCIN TO INHIBIT RESPONSE AND INDUCE TOLERANCE TO GENE THERAPY VECTOR AND ENCODED TRANSGENE PRODUCTS 审中-公开
标题翻译： RAPAMYCIN对抑制反应的使用和对基因治疗载体和编码的转基因产品的耐受性
公开(公告)号：US20080096808A1
公开(公告)日：2008-04-24
申请号：US11924949
申请日：2007-10-26
申请人： Abraham Scaria
发明人： Abraham Scaria
IPC分类号： A61K31/70 , A61K38/00 , A61P43/00
CPC分类号： A61K31/435 , A61K31/015 , A61K31/375 , A61K31/4745 , A61K31/70 , A61K38/37 , A61K38/465 , A61K38/47 , A61K38/4846 , A61K39/395 , A61K48/00 , C12N2799/021 , A61K2300/00
摘要： Disclosed are methods for transient co-administration of rapamycin together with a gene therapy vector encoding a transgene. The present invention is directed to inhibiting the immune response of a host to the administered gene therapy vector and encoded trans gene product, thus allowing persistent trans gene expression and repeated administration of the gene therapy product to the host. The present invention is also of relevance in genetic disease patients that mount immune responses to protein replacement therapies in which case the present invention provides for transient co-administration of rapamycin together with protein replacement therapy. In a further aspect of the invention, co-administration of rapamycin could inhibit a secondary immune response in a host that has been pre-immunized with the gene therapy vector or pre-immunized with the protein product encoded by the transgene.
摘要翻译：公开了雷帕霉素与编码转基因的基因治疗载体的瞬时共同给药的方法。本发明涉及抑制宿主对所施用的基因治疗载体和编码的转基因产物的免疫应答，从而允许持续的转基因表达并将基因治疗产物重复施用于宿主。本发明在对蛋白质替代疗法产生免疫应答的遗传疾病患者中也是相关的，在这种情况下本发明提供雷帕霉素与蛋白质替代疗法的暂时共同给药。在本发明的另一方面，雷帕霉素的共同给药可以抑制已经用基因治疗载体预先免疫的宿主中的第二免疫应答或者用转基因编码的蛋白质产物预先免疫。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式